89 related articles for article (PubMed ID: 15677349)
41. Inhibition of cytochrome P450 2A participating in coumarin 7-hydroxylation in pig liver microsomes.
Liu ZY; Dai MH; Tao YF; Chen DM; Yuan ZH
J Vet Pharmacol Ther; 2011 Oct; 34(5):424-9. PubMed ID: 21244437
[TBL] [Abstract][Full Text] [Related]
42. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
Fischer V; Rodríguez-Gascón A; Heitz F; Tynes R; Hauck C; Cohen D; Vickers AE
Drug Metab Dispos; 1998 Aug; 26(8):802-11. PubMed ID: 9698296
[TBL] [Abstract][Full Text] [Related]
43. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.
Taavitsainen P; Juvonen R; Pelkonen O
Drug Metab Dispos; 2001 Mar; 29(3):217-22. PubMed ID: 11181487
[TBL] [Abstract][Full Text] [Related]
44. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases.
Sridar C; Goosen TC; Kent UM; Williams JA; Hollenberg PF
Drug Metab Dispos; 2004 Jun; 32(6):587-94. PubMed ID: 15155549
[TBL] [Abstract][Full Text] [Related]
45. Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19.
Krausz KW; Goldfarb I; Buters JT; Yang TJ; Gonzalez FJ; Gelboin HV
Drug Metab Dispos; 2001 Nov; 29(11):1410-23. PubMed ID: 11602516
[TBL] [Abstract][Full Text] [Related]
46. Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6 beta-hydroxylation activity by cyclophosphamide and ifosfamide in vitro.
Murray M; Butler AM; Stupans I
J Pharmacol Exp Ther; 1994 Aug; 270(2):645-9. PubMed ID: 8071856
[TBL] [Abstract][Full Text] [Related]
47. In vitro drug-drug interaction screens for canine veterinary medicines: evaluation of cytochrome P450 reversible inhibition.
Aidasani D; Zaya MJ; Malpas PB; Locuson CW
Drug Metab Dispos; 2008 Aug; 36(8):1512-8. PubMed ID: 18448570
[TBL] [Abstract][Full Text] [Related]
48. Bromopropylate: induction of hepatic cytochromes P450 and absence of covalent binding to DNA in mouse liver.
Thomas H; Sagelsdorff P; Molitor E; Skripsky T; Waechter F
Toxicol Appl Pharmacol; 1994 Nov; 129(1):155-62. PubMed ID: 7974489
[TBL] [Abstract][Full Text] [Related]
49. Inactivation of cytochromes P450 2B protects against cocaine-mediated toxicity in rat liver slices.
Poet TS; Brendel K; Halpert JR
Toxicol Appl Pharmacol; 1994 May; 126(1):26-32. PubMed ID: 8184429
[TBL] [Abstract][Full Text] [Related]
50. Escherichia coli expression of site-directed mutants of cytochrome P450 2B1 from six substrate recognition sites: substrate specificity and inhibitor selectivity studies.
He YQ; He YA; Halpert JR
Chem Res Toxicol; 1995 Jun; 8(4):574-9. PubMed ID: 7548737
[TBL] [Abstract][Full Text] [Related]
51. Cytochrome P450-mediated metabolism and cytotoxicity of aflatoxin B(1) in bovine hepatocytes.
Kuilman ME; Maas RF; Fink-Gremmels J
Toxicol In Vitro; 2000 Aug; 14(4):321-7. PubMed ID: 10906438
[TBL] [Abstract][Full Text] [Related]
52. Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs.
Ishizuka M; Nagai S; Sakamoto KQ; Fujita S
Xenobiotica; 2007 May; 37(5):503-13. PubMed ID: 17523053
[TBL] [Abstract][Full Text] [Related]
53. Cannabidiol and cannabidiolic acid: Preliminary in vitro evaluation of metabolism and drug-drug interactions involving canine cytochrome P-450, UDP-glucuronosyltransferase, and P-glycoprotein.
Court MH; Mealey KL; Burke NS; Jimenez TP; Zhu Z; Wakshlag JJ
J Vet Pharmacol Ther; 2024 Jan; 47(1):1-13. PubMed ID: 37469115
[TBL] [Abstract][Full Text] [Related]
54. Absolute Quantitation of Drug-Metabolizing Cytochrome P450 Enzymes and Accessory Proteins in Dog Liver Microsomes Using Label-Free Standard-Free Analysis Reveals Interbreed Variability.
Martinez SE; Shi J; Zhu HJ; Perez Jimenez TE; Zhu Z; Court MH
Drug Metab Dispos; 2019 Nov; 47(11):1314-1324. PubMed ID: 31427433
[TBL] [Abstract][Full Text] [Related]
55. Tramadol metabolism to O-desmethyl tramadol (M1) and N-desmethyl tramadol (M2) by dog liver microsomes: Species comparison and identification of responsible canine cytochrome P-450s (CYPs).
Perez Jimenez TE; Mealey KL; Grubb TL; Greene SA; Court MH
Drug Metab Dispos; 2016 Dec; 44(12):1963-1972. PubMed ID: 27758804
[TBL] [Abstract][Full Text] [Related]
56. N-alkylprotoporphyrin formation and hepatic porphyria in dogs after administration of a new antiepileptic drug candidate: mechanism and species specificity.
Nicolas JM; Chanteux H; Mancel V; Dubin GM; Gerin B; Staelens L; Depelchin O; Kervyn S
Toxicol Sci; 2014 Oct; 141(2):353-64. PubMed ID: 24973095
[TBL] [Abstract][Full Text] [Related]
57. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis.
Afzelius L; Zamora I; Ridderström M; Andersson TB; Karlén A; Masimirembwa CM
Mol Pharmacol; 2001 Apr; 59(4):909-19. PubMed ID: 11259637
[TBL] [Abstract][Full Text] [Related]
58. A Comprehensive Investigation of Dog Cytochrome P450 3A (CYP3A) Reveals a Functional Role of Newly Identified CYP3A98 in Small Intestine.
Uno Y; Jikuya S; Noda Y; Murayama N; Yamazaki H
Drug Metab Dispos; 2023 Jan; 51(1):38-45. PubMed ID: 35772769
[TBL] [Abstract][Full Text] [Related]
59. Mechanism-based inactivation of lung-selective cytochrome P450 CYP2F enzymes.
Kartha JS; Yost GS
Drug Metab Dispos; 2008 Jan; 36(1):155-62. PubMed ID: 17962375
[TBL] [Abstract][Full Text] [Related]
60. Expression and characterization of dog CYP2D15 using baculovirus expression system.
Tasaki T; Nakamura A; Itoh S; Ohashi K; Yamamoto Y; Masuda M; Iwata H; Kazusaka A; Kamataki T; Fujita S
J Biochem; 1998 Jan; 123(1):162-8. PubMed ID: 9504424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
